Business
Serina Therapeutics to Present at FORCE Family Office Investor Webinar on June 26, 2025
How Parkinson’s affects million – and why current treatments are not enoughContinuous dopaminergic stimulation (CDS): a next-gen approach to Parkinson’s careSerina’s drug candidate SER-252 is designed to deliver continuous symptom reliefJoin Serina CEO Steve Ledger for this live event hosted by FORCE Family Office HUNTSVILLE, AL, June 23, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platf
About this update from Serina Therapeutics, Inc.
[{"type":"image","alt":"Serina Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Serina Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":84,"url":"https://media.zenfs.com/en/globenewswire.com/f5ef3cecb8662785323a6a370007d6d1"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/vVhesNODR8eRh4qa0Kn9PQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/f5ef3cecb8662785323a6a370007d6d1","width":300,"height":84}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"How Parkinson’s affects million – and why current treatments are not enough","length":75,"tagName":"p"}]},{"val":[{"type":"text","content":"Continuous dopaminergic stimulation (CDS): a next-gen approach to Parkinson’s care","length":82,"tagName":"p"}]},{"val":[{"type":"text","content":"Serina’s drug candidate SER-252 is designed to deliver continuous symptom relief","length":80,"tagName":"p"}]},{"val":[{"type":"text","content":"Join Serina CEO Steve Ledger for this live event hosted by FORCE Family Office","length":78,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":315,"olType":false},{"type":"text","content":"HUNTSVILLE, AL, June 23, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, is pleased to announce that Chief Executive Officer Steve Ledger will present at an upcoming FORCE Family Office investor webinar titled "New Drug Optimization Platform to Transform Parkinson’s Care.” The Event is scheduled to take place on Thursday, June 26, 2025, at 12:00 p.m. ET / 9:00 a.m. PT.","length":542,"tagName":"p"},{"type":"text","content":"In this presentation, Mr. Ledger will discuss how advanced Parkinson’s disease impacts millions of people worldwide by affecting their ability to move and maintain quality of life. He will highlight the limitations of current medications, which often wear off quickly or cause unwanted side effects like tremors or stiffness. SER-252 is Serina’s propriety polymer conjugate of apomorphine, a clinically proven dopamine agonist, which is designed to deliver continuous dopaminergic stimulation (CDS), which aims to provide smoother, longer-lasting symptom control and g...